Catalyst Pharmaceuticals (CPRX) Share-based Compensation (2010 - 2026)

Catalyst Pharmaceuticals has reported Share-based Compensation for 17 years, with the latest figure at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 7.01% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $25.2 million (up 26.87% YoY), and the FY2025 full-year result was $24.8 million, up 11.36% from the prior year.
• Share-based Compensation for Q1 2026 stood at $6.3 million, up from $5.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $8.2 million in Q1 2024, with the low at $1.9 million in Q1 2022.
• Historically, Share-based Compensation has averaged $4.4 million across 5 years, with a median of $4.4 million in 2024.
• Annual changes were most pronounced in 2024 — Share-based Compensation jumped 185.2% — and 2025, when it fell 29.07%.
• Catalyst Pharmaceuticals' Share-based Compensation stood at $1.9 million in 2022, then surged by 120.66% to $4.2 million in 2023, then increased by 21.67% to $5.2 million in 2024, then grew by 9.48% to $5.7 million in 2025, then gained by 10.58% to $6.3 million in 2026.
• The last three Share-based Compensation figures came in at $6.3 million (Q1 2026), $5.7 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.